Sugi Predict

Sugi Predict / Compounds / SCHEMBL1645544

SCHEMBL1645544

SCHEMBL1645544

Cc1cc(N(C[C@@H](C)F)S(=O)(=O)c2cccnc2)c(OCc2ccc(C(=O)O)cc2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TRPM8 Q7Z2W7 4/20 0.39
▸ RXRA P19793 2/20 0.38
▸ RXRB P28702 2/20 0.38
▸ RXRG P48443 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MRGPRX4 Q96LA9 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1645971 1.00 NR1H4 (0.41) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12361938 1.00 NR1H4 (0.41) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL214627 0.94 NR1H4 (0.48) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL1647319 0.94 KEAP1 (0.42) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12361912 0.94 KEAP1 (0.42) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL1647311 0.94 KEAP1 (0.42) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12361845 0.92 LMNA (0.40) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12361842 0.92 LMNA (0.40) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12361839 0.92 LMNA (0.40) NR1H4LMNAHTTNPSR1KEAP1
SCHEMBL12380745 0.91 RORC (0.43) HTTKEAP1NFE2L2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201616-A1 SULFONAMIDE COMPOUNDS OR SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US claimed
EP-2305641-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2011-04-06 — — EP claimed
US-8314240-B2 Sulfonamide compounds or salts thereof ASTELLAS PHARMA INC. (JP) 2012-11-20 — — US disclosed
US-8314240-B2 Sulfonamide compounds or salts thereof ASTELLAS PHARMA INC. (JP) 2012-11-20 — — US disclosed
US-8314240-B2 Sulfonamide compounds or salts thereof ASTELLAS PHARMA INC. (JP) 2012-11-20 — — US disclosed
US-20110201616-A1 SULFONAMIDE COMPOUNDS OR SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US disclosed
US-20110201616-A1 SULFONAMIDE COMPOUNDS OR SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US disclosed
US-20110201616-A1 SULFONAMIDE COMPOUNDS OR SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US disclosed
EP-2305641-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2011-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201616-A1 SULFONAMIDE COMPOUNDS OR SALTS THEREOF PTGER1, PTGER2, GPER1 NR1H4 1129/4885LMNA 4382/4885HTT 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.